Alleviation of isolated nail lichen planus by the JAK1/2 inhibitor Baricitinib: a case report

被引：4
|
作者：
He, Juan [1 ]
Weng, Tengyu [1 ]
Zhu, Wenwei [1 ]
Yang, Yi [2 ]
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Dermatol, Beijing, Peoples R China
[2] Third Med Ctr Chinese Peoples Liberat Army, Dept Dermatol, Beijing, Peoples R China
来源：
JOURNAL OF DERMATOLOGICAL TREATMENT | 2023年 / 34卷 / 01期
关键词：
D O I：
10.1080/09546634.2023.2274816
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia
    Luschnig, Petra
    Kienzl, Melanie
    Roula, David
    Pilic, Johannes
    Atallah, Reham
    Heinemann, Akos
    Sturm, Eva M.
    BIOCHEMICAL PHARMACOLOGY, 2021, 192
  • [32] The JAK1/2 Inhibitor Baricitinib Mitigates the Spike-Induced Inflammatory Response of Immune and Endothelial Cells In Vitro
    Barilli, Amelia
    Visigalli, Rossana
    Ferrari, Francesca
    Luciani, Giulia Recchia
    Soli, Maurizio
    Dall'Asta, Valeria
    Rotoli, Bianca Maria
    BIOMEDICINES, 2022, 10 (09)
  • [33] Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients
    Kim, Hanna
    Brooks, Kristina M.
    Tang, Cheng Cai
    Wakim, Paul
    Blake, Mary
    Brooks, Stephen R.
    Sanchez, Gina A. Montealegre
    de Jesus, Adriana A.
    Huang, Yan
    Tsai, Wanxia Li
    Gadina, Massimo
    Prakash, Apurva
    Janes, Jonathan Marcus
    Zhang, Xin
    Macias, William L.
    Kumar, Parag
    Goldbach-Mansky, Raphaela
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (02) : 364 - 373
  • [34] A CASE STUDY OF RESENSITIZATION TO RUXOLITINIB, A JAK1/JAK2 INHIBITOR, IN A PATIENT WITH MYELOFIBROSIS (MF)
    Gisslinger, H.
    Skrabs, C.
    Gisslinger, B.
    Schoder, R.
    Muellauer, L.
    Kralovics, R.
    HAEMATOLOGICA, 2013, 98 : 346 - 347
  • [35] Corneal perforation associated with isolated ocular lichen planus: a case report
    Gomez-Elizondo, Daniela E.
    Lopez-Martinez, Mariana
    Ruiz-Lozano, Raul Eduardo
    Valdez-Garcia, Jorge E.
    Hernandez-Camarena, Julio C.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2021, 31 (06) : NP9 - NP12
  • [36] Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib
    Wei, Qing
    Xu, Jie
    BLOOD, 2024, 144 (02) : 238 - 238
  • [37] JAK1/2 pathway-specific treatment of generalized granuloma annulare with baricitinib
    Jadoul, A.
    Huygen, L.
    Leemans, G.
    Grosber, M.
    Krohn, I. K.
    Gutermuth, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S340 - S340
  • [38] Tofacitinib, a JAK1/3 Inhibitor As Treatment for Linear IgA Bullous Dermatosis: A Case Report
    Fan, Birao
    Wang, Mingyue
    DERMATITIS, 2023, 34 (02) : 160 - +
  • [39] JAK1/2 pathway-specific treatment of disseminated granuloma annulare with baricitinib
    Jadoul, A.
    Huygen, L.
    Leemans, G.
    Grosber, M.
    Krohn, I. Kortekaas
    Gutermuth, J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (08) : E1006 - E1008
  • [40] JAK1/2 pathway-specific treatment of generalized granuloma annulare with baricitinib
    Jadoul, A.
    Huygen, L.
    Leemans, G.
    Grosber, M.
    Krohn, I. Kortekaas
    Gutermuth, J.
    EXPERIMENTAL DERMATOLOGY, 2024, 33 (03)
12345